Nevro (NYSE:NVRO) today said it appointed Julie Dewey as VP of investor relations and corporate communications, effective immediately. Dewey has more than 25 years of experience in investor relations, corporate communications and marketing in several medical technology companies. She most recently served as senior VP and chief communications officer of Wright Medical, which was recently acquired […]
Neuromodulation/Neurostimulation
Abbott launches RF pain treatment device
Abbott (NYSE:ABT) announced today that it launched its IonicRF generator for non-surgical treatment for nervous system pain management. The recently FDA-cleared device is designed for minimally invasive treatment through radiofrequency ablation, using heat to target specific nerves and block pain signals from reaching the brain. According to a news release. it’s the first Abbott-developed RF ablation […]
Nevro rises on Street-beating Q3
Nevro (NYSE:NVRO) shares ticked up today on third-quarter results that came in ahead of the consensus forecast. The Redwood City, Calif.-based chronic pain treatment developer posted losses of -$10 million, or -29¢ per share, on sales of $108.5 million for the three months ended Sept. 30, 2020, for a 44.1% bottom-line gain on sales growth of […]
Axonics beats sales estimates in Q3
Axonics (NSDQ: AXNX) saw its stock tick up by 5.47% at the close of trading on third-quarter results that beat the consensus earnings forecast. The Irvine, Calif.-based sacral neuromodulation technologies company had a -$9.2 million loss, or -$0.24 per share, in the quarter ended September 30, 2020. The consensus estimate for the stock was a loss of […]
Salvia BioElectronics wins FDA breakthrough nod for neurostim migraine treatment device
Dutch startup Salvia BioElectronics this week said it received FDA breakthrough device designation for its implantable neurostimulation system to treat chronic migraine. Salvia’s system is based on a novel device concept using thin and conforming bioelectronic foils that it says uniquely adapt to the anatomy of the head. “The FDA breakthrough device designation of our […]
Neuros Medical raises $37M
Neuromodulation technology developer Neuros Medical filed an SEC Form D to confirm the sale of nearly $37 million in equity. Willoughby Hills, Ohio-based Neuros Medical made the first sale in the new notice offering on Oct. 27, 2020, and listed in the SEC filing that it does not intend for it to last longer than […]
CVRx secures reimbursement win from CMS
CVRx announced that it received the CMS inpatient new technology add-on payment (NTAP) for its Barostim Neo implantable device. Effective Oct. 1, 2020, and ranging over a three-year duration, Medicare is slated to provide an add-on payment for Barostim Neo worth up to 65% of the device cost (up to a maximum amount allowed of […]
Medtronic issues safety notice for InterStim SureScan MRI leads
Medtronic (NYSE:MDT) recently issued an urgent field safety notice to alert users to a potential issue with its InterStim SureScan MRI leads. Fridley, Minn.-based Medtronic said in the notice out of Germany that the Medtronic Model 3560030/3560022 percutaneous extension is intended for use with the Model 978A1/978B1 InterStim SureScan MRI leads during an advanced evaluation to […]
Cala Health wins FDA breakthrough nod for tremor treating therapy
Cala Health announced today that it received FDA breakthrough device designation for its Cala Trio treatment for action tremors in people with Parkinson’s disease. Burlingame, Calif.-based Cala Health’s Cala Trio is FDA cleared to relieve hand tremors from essential tremor (ET), but the company is now nearing the initiation of clinical trials to evaluate the […]
CB Insights reports digital health, global healthcare investment funding records
CB Insights reported record funding for global healthcare and digital health, among other milestones during the third quarter. Global healthcare investments to private companies hit a new quarterly record of $21.8 billion in the third quarter of this year, with a total of 1,539 equity investments in the three-month period growing 18% from the previous […]
Axonics launches SNS postmarket study
Axonics Modulation Technologies (NSDQ:AXNX) announced today that it is launching a post-market clinical registry study for its r-SNM system. Irvine, Calif.-based Axonics’ implantable sacral neuromodulation (SNM) system is designed for treating urinary and bowel dysfunction with a battery life of 15 years or more. The Axonics Sacral Neuromodulation System Registry (Artistry) study is a prospective, multicenter […]
